Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://link.springer.com/protocol/10.1007/978-1-60761-416-6_3, but it redirected us to https://link.springer.com/protocol/10.1007/978-1-60761-416-6_3. The analysis below is for the second page.

Title[redir]:
Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer | SpringerLink
Description:
The generation of genetically engineered mouse models (GEMMs) that mimic breast cancer in humans provides new tools to investigate mechanisms of drug resistance in vivo. The advantages are manifold: inbred mice do not have the genomic heterogeneity seen in patients;...

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Science
  • Education

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We can't figure out the monetization strategy.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Doi.org could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {πŸ”}

cancer, pubmed, google, scholar, article, cas, resistance, breast, drug, mouse, models, rottenberg, jonkers, tumors, rev, genetically, engineered, mammary, nat, privacy, cookies, content, information, publish, research, multidrug, protocol, therapy, search, pajic, molecular, mice, cells, access, borst, apoptosis, nature, proc, natl, acad, sci, usa, data, log, journal, sven, jos, biology, mechanisms, tumor,

Topics {βœ’οΈ}

springer science+business media human brca1-mutated basal protocol multi-drug resistance marina pajicΒ &Β jos jonkers brca1-deficient mammary tumors multi-drug resistance privacy choices/manage cookies studying drug resistance conditional mouse models humana press van der gulden gottesman mm reversing drug resistance drug resistance phenotype journal finder publish cancer drug resistance cancer drug development accelerated preclinical testing cancer sven rottenberg breast cancer protocol targeting multidrug resistance mimic breast cancer hereditary breast cancer mammalian abc transporters schmitt ca parp inhibitor azd2281 spontaneous immune responses conditional mouse model dutch cancer society netherlands cancer institute vivo pharmacology models conditions privacy policy author information authors editor information editors european economic area efficient tumour formation bmc cancer 6 anti-angiogenic therapy accepting optional cookies modeling therapy resistance chapter log main content log mouse models online protocol rottenberg jos jonkers drug resistance journal publish sven rottenberg ludwig ja

Questions {❓}

  • De Visser KE (2008) Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both?

Schema {πŸ—ΊοΈ}

ScholarlyArticle:
      headline:Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer
      pageEnd:45
      pageStart:33
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-60761-416-6.jpg
      genre:
         Springer Protocols
      isPartOf:
         name:Multi-Drug Resistance in Cancer
         isbn:
            978-1-60761-416-6
            978-1-60761-415-9
         type:Book
      publisher:
         name:Humana Press
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sven Rottenberg
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Marina Pajic
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jos Jonkers
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      keywords:GEMM, Breast cancer, Orthotopic transplantation, BRCA1, BRCA2, E-cadherin, ATP-binding cassette (ABC) transporter, FACS sorting, Tumor-initiating cells
      description:The generation of genetically engineered mouse models (GEMMs) that mimic breast cancer in humans provides new tools to investigate mechanisms of drug resistance in vivo. The advantages are manifold: inbred mice do not have the genomic heterogeneity seen in patients; mammary tumors are superficial and therefore easily accessible for measurement and sampling pre- and posttreatment; tumors can be transplanted orthotopically into syngeneic, immunocompetent animals; and tumor cells can be modified in vitro (e.g., gene overexpression, shRNA knockdown, insertional mutagenesis) prior to transplantation. Here, we provide an overview with experimental details of various approaches to study mechanisms of drug resistance in GEMMs for breast cancer.
      datePublished:2010
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Multi-Drug Resistance in Cancer
      isbn:
         978-1-60761-416-6
         978-1-60761-415-9
Organization:
      name:Humana Press
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sven Rottenberg
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Marina Pajic
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Jos Jonkers
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
      name:Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {πŸ”—}(144)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Pbgrd

4.36s.